Respiratory Syncytial Virus Infections Clinical Trial
— MEDI8897 Ph2bOfficial title:
A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
| Verified date | September 2019 |
| Source | MedImmune LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.
| Status | Completed |
| Enrollment | 1453 |
| Est. completion date | December 6, 2018 |
| Est. primary completion date | July 17, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A to 365 Days |
| Eligibility |
Key Inclusion Criteria: 1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA. 2. Infants who are entering their first full RSV season at the time of screening. Key Exclusion Criteria: 1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab. 2. Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness within 7 days prior to randomization. 3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization. 4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection. 5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination. |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Research Site | Bahía Blanca | |
| Argentina | Research Site | Guaymallen Mendoza | |
| Australia | Research Site | Parkville | |
| Australia | Research Site | Subiaco | |
| Belgium | Research Site | Gent | |
| Belgium | Research Site | Mons | |
| Brazil | Research Site | Botucatu | |
| Brazil | Research Site | Campinas | |
| Brazil | Research Site | Canoas | |
| Brazil | Research Site | Curitiba | |
| Brazil | Research Site | Juiz de Fora | |
| Brazil | Research Site | Passo Fundo | |
| Bulgaria | Research Site | Pleven | |
| Bulgaria | Research Site | Plovdiv | |
| Bulgaria | Research Site | Ruse | |
| Bulgaria | Research Site | Sofia | |
| Bulgaria | Research Site | Sofia | |
| Canada | Research Site | Montreal | Quebec |
| Chile | Research Site | Maipu | |
| Chile | Research Site | Santiago | |
| Chile | Research Site | Santiago | |
| Chile | Research Site | Santiago | |
| Chile | Research Site | Santiago | |
| Chile | Research Site | Valdivia | |
| Chile | Research Site | Viña del Mar | |
| Czechia | Research Site | Havlickuv Brod | |
| Czechia | Research Site | Praha 4 | |
| Czechia | Research Site | Praha 4 | |
| Estonia | Research Site | Tallinn | |
| Estonia | Research Site | Tartu | |
| Finland | Research Site | Tampere | |
| Finland | Research Site | Turku | |
| France | Research Site | Bordeaux | |
| France | Research Site | Brest | |
| France | Research Site | Bron | |
| France | Research Site | Caen Cedex | |
| France | Research Site | Dijon | |
| France | Research Site | Tours CEDEX 9 | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Budapest | |
| Hungary | Research Site | Gyula | |
| Hungary | Research Site | Kecskemét | |
| Hungary | Research Site | Miskolc | |
| Hungary | Research Site | Nagykanizsa | |
| Hungary | Research Site | Nyireyghaza | |
| Hungary | Research Site | Sopron | |
| Hungary | Research Site | Szeged | |
| Hungary | Research Site | Szekszárd | |
| Hungary | Research Site | Veszprém | |
| Italy | Research Site | Genova | |
| Italy | Research Site | Padova | |
| Italy | Research Site | Torino | |
| Italy | Research Site | Verona | |
| Latvia | Research Site | Jekabpils | |
| Latvia | Research Site | Riga | |
| Latvia | Research Site | Valmiera | |
| Lithuania | Research Site | Kaunas | |
| Lithuania | Research Site | Kaunas | |
| New Zealand | Research Site | Christchurch | |
| New Zealand | Research Site | Otahuhu | |
| New Zealand | Research Site | Wellington | |
| Poland | Research Site | Bydgoszcz | |
| Poland | Research Site | Gdansk | |
| Poland | Research Site | Krakow | |
| Poland | Research Site | Krakow | |
| Poland | Research Site | Leczna | |
| South Africa | Research Site | Cape Town | |
| South Africa | Research Site | Cape Town | |
| South Africa | Research Site | Claremont | |
| South Africa | Research Site | Durban | |
| South Africa | Research Site | Johannesburg | |
| South Africa | Research Site | Johannesburg | |
| South Africa | Research Site | Pietermaritzburg | |
| South Africa | Research Site | Pretoria | |
| Spain | Research Site | Alicante | |
| Spain | Research Site | Boadilla del Monte | |
| Spain | Research Site | Cordoba | |
| Spain | Research Site | Granada | |
| Spain | Research Site | Lleida | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Málaga | |
| Spain | Research Site | San Juan de Alicante | |
| Spain | Research Site | Sant Cugat del Valles | |
| Spain | Research Site | Santiago de Compostela | |
| Spain | Research Site | Valencia | |
| Sweden | Research Site | Stockholm | |
| Sweden | Research Site | Stockholm | |
| Turkey | Research Site | Adana | |
| Turkey | Research Site | Ankara | |
| Turkey | Research Site | Antalya | |
| Turkey | Research Site | Izmir | |
| Turkey | Research Site | Izmir | |
| Turkey | Research Site | Kocaeli | |
| United Kingdom | Research Site | Brighton | |
| United Kingdom | Research Site | Bristol | |
| United Kingdom | Research Site | London | |
| United Kingdom | Research Site | Oxford | |
| United Kingdom | Research Site | Southampton | |
| United States | Research Site | Anaheim | California |
| United States | Research Site | Anaheim | California |
| United States | Research Site | Atlanta | Georgia |
| United States | Research Site | Augusta | Georgia |
| United States | Research Site | Aurora | Colorado |
| United States | Research Site | Birmingham | Alabama |
| United States | Research Site | Boone | North Carolina |
| United States | Research Site | Charleston | South Carolina |
| United States | Research Site | Chicago | Illinois |
| United States | Research Site | Cincinnati | Ohio |
| United States | Research Site | Cleveland | Ohio |
| United States | Research Site | Colorado Springs | Colorado |
| United States | Research Site | Columbia | Missouri |
| United States | Research Site | Columbus | Ohio |
| United States | Research Site | Columbus | Ohio |
| United States | Research Site | Dayton | Ohio |
| United States | Research Site | Detroit | Michigan |
| United States | Research Site | Downey | California |
| United States | Research Site | Edinburg | Texas |
| United States | Research Site | Erie | Pennsylvania |
| United States | Research Site | Fort Worth | Texas |
| United States | Research Site | Gainesville | Florida |
| United States | Research Site | Galveston | Texas |
| United States | Research Site | Gresham | Oregon |
| United States | Research Site | Hartford | Connecticut |
| United States | Research Site | Huntington | West Virginia |
| United States | Research Site | Jackson | Mississippi |
| United States | Research Site | Layton | Utah |
| United States | Research Site | Lincoln | Nebraska |
| United States | Research Site | Long Beach | California |
| United States | Research Site | Longview | Texas |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Madison | Wisconsin |
| United States | Research Site | Memphis | Tennessee |
| United States | Research Site | Mineola | New York |
| United States | Research Site | Morgantown | West Virginia |
| United States | Research Site | New Hyde Park | New York |
| United States | Research Site | North Charleston | South Carolina |
| United States | Research Site | Oak Lawn | Illinois |
| United States | Research Site | Oklahoma City | Oklahoma |
| United States | Research Site | Omaha | Nebraska |
| United States | Research Site | Omaha | Nebraska |
| United States | Research Site | Omaha | Nebraska |
| United States | Research Site | Orem | Utah |
| United States | Research Site | Orlando | Florida |
| United States | Research Site | Paramount | California |
| United States | Research Site | Park Ridge | Illinois |
| United States | Research Site | Pittsburgh | Pennsylvania |
| United States | Research Site | Raleigh | North Carolina |
| United States | Research Site | San Antonio | Texas |
| United States | Research Site | San Diego | California |
| United States | Research Site | Seattle | Washington |
| United States | Research Site | Sioux Falls | South Dakota |
| United States | Research Site | South Bend | Indiana |
| United States | Research Site | South Miami | Florida |
| United States | Research Site | Stony Brook | New York |
| United States | Research Site | Syracuse | New York |
| United States | Research Site | Syracuse | Utah |
| United States | Research Site | West Covina | California |
| United States | Research Site | Woburn | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| MedImmune LLC |
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Estonia, Finland, France, Hungary, Italy, Latvia, Lithuania, New Zealand, Poland, South Africa, Spain, Sweden, Turkey, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Confirmed Lower Respiratory Tract Infection (LRTI) | The determination of medically attended RSV LRTI is based on objective clinical LRTI criteria and RSV test results obtained from analyzing the respiratory secretions using a validated RSV real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the detection of RSV A or RSV B subtypes. Criteria for LRTI included documented physical exam findings of rhonchi, rales, crackles, or wheeze and any of the following: increased respiratory rate at rest (for age less than (<) 2 months: greater than or equal to (>=) 60 breaths/min; 2-6 months: >= 50 breaths/min; and for > 6 months - 2 years, >= 40 breaths/min), or hypoxemia (in room air - oxygen saturation < 95% at altitudes less than or equal to (<=) 1800 meters or < 92% at altitudes > 1800 meters), or clinical signs of severe respiratory disease or dehydration secondary to inadequate oral intake due to respiratory distress (need for intravenous fluid). | From Day 1 through Day 151 | |
| Secondary | Number of Participants Hopitalized Due to Respiratory Syncytial Virus (RSV) Confirmed Lower Respiartory Tract Infection (LRTI) | A RSV hospitalization is defined as either 1) a respiratory hospitalization with a positive RSV test within 2 days of hospitalization (primary) or 2) new onset of respiratory symptoms in an already hospitalized child, with an objective measure of worsening respiratory status and positive RSV test (nosocomial). | From Day 1 through Day 151 | |
| Secondary | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. | From Day 1 through Day 361 | |
| Secondary | Number of Participants With Adverse Events of Special Interest (AESIs) and New Onset Chronic Diseases (NOCDs) | An AESI was one of scientific and medical interest specific to understanding of study drug and may have required close monitoring and rapid communication by investigator to the sponsor. An AESI may be serious or non-serious. A NOCD is a newly diagnosed medical condition that is of a chronic, ongoing nature. It is observed after receiving study drug and is assessed by investigator as medically significant. | From Day 1 through Day 361 | |
| Secondary | Serum Concentration of MEDI8897 | Days 91, 151, and 361 | ||
| Secondary | Elimination Half-life (t1/2) of MEDI8897 | Terminal elimination half-life (t½) is the time required for half of the drug to be eliminated from the serum. | Day 91 through Day 361 | |
| Secondary | Number of Participants With Positive Anti-drug Antibodies to MEDI8897 | The number of participants with positive serum antibodies to MEDI8897 are reported. | Days 91, 151, and 361 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
| Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
| Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
| Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
| Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
| Terminated |
NCT02948127 -
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
| Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
| Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
| Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
| Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
| Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
| Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
| Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
| Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 |